Evaluation of Bumetanide’s Effect on Symptom Characteristics in Patients with Obsessive Compulsive Disorder
Phase 2
Recruiting
- Conditions
- Obsessive Compulsive Disorder (OCD).Obsessive-compulsive disorder
- Registration Number
- IRCT20140120016280N3
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 31
Inclusion Criteria
1. Confirmed Diagnosis of Resistant OCD
Age range of 18-50 years
IQ level more than 80 based on Wechsler Adult Intelligence Scale
Exclusion Criteria
Comorbidities like MDD, Bipolar Disorder, Personality Disorder, Schizophrenia
Drug Adverse Effects
Pregnancy, Breast Feeding (Based on self report data and urinary detection)
Drug and alcohol use and dependance (Based on self report data and urinary detection)
Benzodiazepine use within 3 preceding months
Furesemide and other diuretic and cardiovascular drugs use
Sulfur and its derivatives sensitivity
Neurological Disorders(seizure, trauma, ischemic stroke, surgery)
Presence of MRI SCanning absolute and partial contraindications
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Symptom (Obsession and Compulsions) Severity Based on Yale Brown Obsessive Compulsive Disorder Scale. Timepoint: Assessment of Severity and pattern of symptoms : 1. In the beginning of Study and before intervention, 2. 10 days after intervention, 3. 20 days after intervention, 4. 30 days after intervention, 5. 40 days after intervention, 6. 50 days after intervention, 7. 60 days after intervention, 8. 70 days after intervention. Method of measurement: Validated Yale Brown Obsessive Compulsive Disorder Scale.
- Secondary Outcome Measures
Name Time Method Alteration in Neuro-Cognitive Functioning. Timepoint: In the Beginning of Study and then after Study Completion. Method of measurement: the Cambridge Neuropsychological Test Automated Battery (CANTAB).;Assessment of Functional Reorganization of Large Scale Brain Networks. Timepoint: Before the beginning of the clinical trial and immediately after the end of that. Method of measurement: Functional Magnetic Resonance Imaging.;Expression of Na-K-Cl Co transporter (NKCC1) in Lymphocytes of the Peripheral Blood. Timepoint: Before the Beginning of the Clinical Trial and Immediately after that. Method of measurement: Real Time Polymerase Chain Reaction (RT-PCR) and Western Analysis.;Expression of K-Cl Co transporter in lymphocyte of the peripheral blood. Timepoint: Before the beginning of the Clinical Trial and Immediately after that. Method of measurement: Real Time Polymerase Chain Reaction (RT-PCR) and Western Analysis.